Introduction
Chronic kidney disease (CKD) is still a major health problem all over the world. It has been reported that hypertension and diabetes mellitus are histopathologically characterized by interstitial inflammation, tubular atrophy and fibrosis. 1 On the other hand, the incidence of diabetes has increased worldwide. 2 Nephropathy is a major microvascular complication of diabetes mellitus and often leads to terminal renal failure in addition to contributing significantly to cardiovascular morbidity and mortality. 3 Additionally, Diabetic nephropathy can cause the occurrence of renal fibrosis. Renal fibrosis has been regarded to be an aberration of tissue healing process, in which there is progression rather than improvement of scar formation after renal tissue injury. 1 When renal fibrosis occurs, most of the patients will develop to chronic kidney disease (CKD), following with end-stage renal disease (ESRD). 4 In that situation, transplantation is the only effective therapeutic strategy. 5 In addition, it has been reported that patients with CKD account for 10% of the world's population. 4 Therefore, novel effective strategy that inhibits progression of renal fibrosis caused by diabetic nephropathy is of great importance. TGF-β1 was found to promote fibronectin and collagen production by transcriptional activation of the relevant genes. 6 Recent studies have indicated that TGF-β1 plays an important role in the progression of renal fibrosis. 7, 8 In addition, Higgins et al have found that TGF-β1 signaling pathway plays a critical role during the induction of renal fibrosis. 9 Besides, it has been previously reported that activation of TGF-β1 signaling pathway can promote EMT process during the metastasis of pancreatic cancer. 10 Based on these findings, we aimed to explore the relation between TGF-β1 signaling pathway and EMT process during the fibrosis.
Valsartan is an effective drug used to treat hypertension, which is also widely used to treat renal fibrosis.
11 Silibinin (SB) is a polyphenolic flavonoid extracted from milk thistle seeds. 12 It has been reported that silibinin could significantly inhibit the occurrence of renal fibrosis. 13 However, the effect of silibinin in combination with valsartan on renal fibrosis has not been reported yet. In this study, we aimed to investigate the anti-renal fibrosis effect of silibinin in combination with valsartan in vitro and in vivo.
Materials and Methods

Cell Culture
Since it has been previously reported that human renal tubular endothelial cells (HK-2) were used to study renal fibrosis,
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HK-2 cell lines (ATCC, Manassas, VA, USA) were used to examine the effects of silibinin in combination with valsartan on renal fibrosis in vitro. Then, membranes were incubated with secondary antibodies (Goat Anti-Rabbit IgG: Abcam, 1:5000, Cambridge, MA, USA) at room temperature for 1 h. The bands of proteins were visualized using a chemiluminescent detection system (BeyoECL Plus, Beyotime, Shanghai, China). Finally, band densities were examined using IPP Image-Pro Plus software. β-actin was used as the internal control.
In vivo Experiment
Male C57BL/6 mice (30-40 g) were purchased from the Chinese Academy of Science (Shanghai, China) and bred in the animal facility of the Affiliated Hospital of Qingdao University (Qingdao, China). All mice used were housed in specific pathogen-free (SPF) conditions with a 12/12 h light/dark cycle. All animal care and experimental protocols were approved by the Use Committee of the Affiliated Hospital of Qingdao University. National Institutes of Health guide for the care and use of laboratory animals was strictly followed by us.
Mice were fed either a high-fat diet (HFD, 60% fat, 20% protein and 20% carbohydrate; n=48) or a standard diet (n=12) for 30 weeks. Then, mice were divided into five groups: control group (n=12, treated with distilled water); HFD group (n=12, treated with distilled water); HFD+ valsartan (n=12, treated with valsartan dissolved in distilled water); HFD+ silibinin (n=12, treated with silibinin dissolved in distilled water) and HFD+ valsartan+ silibinin (n=12, treated with valsartan and silibinin dissolved in distilled water) in the next 6 weeks. After treatment, body weight of each mouse was examined. Microalbuminuria was tested by mouse microalbuminuria ELISA Kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The kidney of each mouse was dissected and then kidney weight/body weight was examined. The severity of fibrosis was demonstrated by selecting 5 noninterfering fields of each section to calculate the ratio of blue-stained scarred areas to the total area.
Enzyme-Linked Immuno Sorbent Assay (ELISA)
Kidney tissues of mice were collected and weighted. Then, the samples were homogenized with saline according to the previous reference. 15 Finally, the supernatants of the samples were collected and the levels of TNF-α and IL-6 were detected by ELISA kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the instructions of manufacturer.
Histopathologic Analysis
The paraffin-embedded renal tissue sections (2 μm) were stained by hematoxylin-eosin (H&E) and Masson's trichrome to evaluate the symptom of renal fibrosis. The severity of fibrosis was indicated by selecting 10 noninterfering fields of each section to detect the ratio of bluestained scarred areas to the total area. Finally, the severity of fibrosis was observed by Hitachi H7500 transmission electron microscope (Hitachi, Tokyo, Japan).
Statistical Analysis
Statistical analysis was performed by using GraphPad Prism software (version 7, La Jolla, CA, USA). The data were presented as mean ± standard deviation (SD) of at least three independent experiments. One-way ANOVA followed by Tukey's test was performed to analyze difference among groups. P value less than 0.05 was considered as a significant difference.
Result The Cytotoxic Effect of Silibinin or Valsartan on HK-2 Cells
For investigating the cytotoxic effect of silibinin ( Figure 1A ) or valsartan on HK-2 cells, CCK-8 assay was performed. As showed in Figure 1B , compared to 0 μM group, 15 or 30 μM silibinin had no significant effect on cell viability, while 60 or 90 μM silibinin notably decreased the cell viability. These results indicated that high concentration of silibinin (≥ 60 μM) exhibited significant cytotoxicity. Meanwhile, as demonstrated in Figure 1C , 10, 20 or 30 μM valsartan had very limited effect on cell viability, while 50 μM valsartan markedly decreased cell proliferation. Finally, the combination of silibinin (30 μM) and valsartan (50 μM) could significantly increase cytotoxicity, while silibinin (30 μM) in combination with valsartan (30 μM) did not induce the cytotoxicity ( Figure 1D ). Therefore, the nontoxic concentration of 30 μM valsartan and 30 μM silibinin were selected for the following experiments.
Silibinin Significantly Increased the AntiFibrosis Effect of Valsartan in TGF-β1-Treated HK-2 Cells CK-18, MMP9 and α-SMA played critical roles in fibrosis. 16 For the purpose of examining the combined effect of silibinin and valsartan on fibrosis in vitro, the expressions of CK-18, MMP9 and α-SMA in HK-2 cells were detected by qRT-PCR. As revealed in Figure 2A 
Silibinin in Combination with Valsartan Exhibited Significant Anti-Renal Fibrosis in vivo
To further investigate the effect of combination treatment (silibinin plus valsartan) on renal fibrosis in vivo, HFD-fed mice model was established. As illustrated in Figure 5A , the body weight of mice was markedly increased in HFD group compared with control, while valsartan, silibinin or combination treatment had a very limited effect on body weight. On the other hand, kidney weight/body weight and microalbuminuria indicated the severity of kidney disease. 17, 18 In our study, kidney weight/body weight and microalbuminuria of mice analysis indicated that the kidney weight/body weight and microalbuminuria in HFDinduced mice were significantly increased compared with control group, which was markedly reduced by valsartan or silibinin ( Figure 5B and C) . Moreover, combination treatment exhibited better anti-fibrosis effect compared with valsartan or silibinin ( Figure 5B and C) . Then, the results of HE staining demonstrated valsartan or silibinin treatment significantly inhibited renal fibrosis in HFD-fed mice. Meanwhile, the renal fibrosis in HFD-fed mice was further alleviated by the combination treatment, compared with valsartan or silibinin alone ( Figure 5D ). Furthermore, as assayed by masson staining, the symptom of renal fibrosis was significantly increased in HFD mice, which was notably reduced by silibinin, valsartan or combination treatment ( Figure 5E ). Finally, as illustrated in Figure 5F , the area of fibrosis in kidney was significantly increased in HFD-fed mice, which was partly decreased by valsartan or silibinin treatment. Meanwhile, silibinin further increased the anti-fibrosis effect of valsartan treatment. All these data revealed that combination of silibinin with valsartan exhibited better anti-renal fibrosis effect in vivo, compared with silibinin or valsartan alone treatment.
Silibinin in Combination with Valsartan Attenuated the Process of Renal Fibrosis via Suppression of TGF-β1 Pathway in vivo
Finally, to further explore the mechanism by which silibinin in combination with valsartan attenuated the renal fibrosis, the expression of p-smad2 and p-smad3 in kidney tissues of mice was investigated. As indicated in Figure 6A -C, valsartan or silibinin partly downregulated the expressions of p-smad2 and p-smad3 in renal tissues, compared with control group; however, the expressions of these two proteins were completely inhibited by combination treatment. Besides, the levels of TNF-α and IL-6 in kidney tissues of mice were significantly increased by HFD, which were notably decreased by valsartan. Additionally, silibinin significantly increased the anti-inflammatory effect of valsartan on HFDinduced renal fibrosis in vivo ( Figure 6D and E). Taken together, all these results further demonstrated that combination of silibinin with valsartan suppressed the progression of renal fibrosis via suppressing TGF-β1 signaling pathway.
Discussion
In this study, we aimed to investigate the anti-fibrosis effect of silibinin in combination with valsartan in vitro and in vivo. It has been suggested that valsartan as anti-hypertension agent inhibited nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in renal fibrosis, 19 and can be applied in clinical trial as anti-fibrosis agent. 20 Our results confirmed that valsartan inhibited cell proliferation in HK-2 cell line with different concentration. On the other hand, the side effect of valsartan seriously reduced the quality of life of patients who receive valsartan as renal fibrosis therapy. 21 Silibinin are obtained from the medicinal plant Silybum marianum (milk thistle) and have conventionally been applied for the treatment of liver diseases. 22 Previous report has revealed that silibinin was effective in treating neuropathy and hepatopathy. 23 In Figure 6 Silibinin in combination with valsartan inhibited renal fibrosis in vivo by suppression of TGF-β1 pathway. (A) The protein expressions of p-smad2 and p-smad3 in kidney tissues of mice were measured by Western-blot. Quantification of the ratio of (B) p-smad2 and (C) p-smad3 levels by normalizing to β-actin. The levels of (D) TNF-α and (E) IL-6 in kidney tissues of mice were detected by ELISA kit. addition, some natural properties of other medicinal plant showed anti-fibrosis ability in vitro. 24 The results of our current research were similar to these previous studies, indicating that silibinin could be regarded as another anti-fibrosis agent. The present data indicated that silibinin notably increased the valsartan-induced anti-fibrosis activities in vitro and in vivo without toxic effects. This finding was similar to the previous study that combination of curcumin, vorinostat and silibinin could reverse nerve cell toxicity. 25 Moreover, our results indicated that silibinin, valsartan or combination treatment (silibinin plus valsartan) had a very limited effect on body weight of mice, which suggested that this treatment strategy had no significant systemic toxicity. Additionally, silibinin enhanced the anti-fibrosis of valsartan in vitro via downregulating the expression of MMP9, α-SMA and upregulating the expression of CK-18. Kosasih et al found that CK-18 played a critical role in progression of liver fibrosis. 26 On the other hand, Notch3 ameliorated cardiac fibrosis through inhibiting the expression of MMP9 and α-SMA. 27 Similar to these results, combination of silibinin with valsartan could inhibit renal fibrosis via suppression of MMP9, α-SMA and increase of CK-18 in TGF-β1-treated HK-2 cells. In addition, CK-18 and α-SMA played crucial roles in EMT process. [28] [29] [30] Our results indicated that valsartan could inactivate CK-18 and α-SMA. Silibinin significantly enhanced the inhibitory effect of valsartan on these two proteins. The results were similar to the previous study, indicating that silibinin enhanced the anti-fibrosis effect of valsartan via downregulation of EMT process. TGF-β1 signaling plays a key role in fibrosis. 8, 31 It was persistently upregulated in fibrosis of various organs (kidney, lung, and heart). 32 It has been reported that TGF-β1 can activate Smad-2/3, and the latter induce transcription of pro-fibrotic genes, factors that can interference this signaling pathway may affect fibrosis. 31 In the present study, we found that silibinin further downregulated the expressions of p-smad2 and p-smad3 in TGF-β1-induced HK-2 cells, compared with valsartan alone. Based on these results, the mechanism underlying the anti-fibrosis effects of silibinin in combination with valsartan in vitro and in vivo was associated with the suppression of TGF-β1 signaling pathways. According to Ko et al, silibinin suppressed the fibrotic responses through inhibition of TGF-β1/Smad 2/3 signaling. 13 Moreover, silibinin attenuated radiation-induced fibrosis via suppressing TGF-β1/Smad signaling in vitro and in vivo. 33 These data were consistent with the results of the present study. Besides, we also found that the expressions of CK-18 and α-SMA were notably upregulated in TGF-β1-treated HK-2 cells. Feng et al have found that upregulation of TGF-β1 signaling could promote the EMT process of melanoma. 34 Our data were consistent with these results, suggesting that TGF-β1 signaling could promote EMT process during the fibrosis. Taken together, silibinin has a potential ability for inhibiting fibrosis by suppression of TGF-β1/Smad 2/3 signaling. Otherwise, EGFR and Wnt signaling pathways are involved in the fibrotic process. 35, 36 However, this study focused only on the effect of silibinin in combination with valsartan on TGF-β1 signaling pathway. Thus, further researches are needed to explore the role of silibinin in combination with valsartan on EGFR or Wnt pathway. Our study firstly revealed that silibinin increased the anti-fibrosis effect of valsartan in vitro and in vivo via suppression of TGF-β1 signaling. These findings indicated that combination of silibinin with valsartan might serve as an effective strategy for the treatment of renal fibrosis caused by diabetic nephropathy.
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